Related Experiment Video
Updated: Sep 29, 2025
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Designing of a Recombinant Multi-Epitopes Based Vaccine against Enterococcus mundtii Using Bioinformatics and
Metab Alharbi1, Abdulrahman Alshammari1, Abdullah F Alasmari1
1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Abstract:
Enterococcus species are an emerging group of bacterial pathogens that have a significant role in hospital-associated infections and are associated with higher mortality and morbidity rates. Among these pathogens, Enterococcus mundtii is one of the causative agents of multiple hospital associated infections. Currently, no commercially available licensed vaccine is present, and multi-drug resistant strains of the pathogen are prominent. Due to several limitations of experimental vaccinology, computational vaccine designing proved to be helpful in vaccine designing against several bacterial pathogens. Herein, we designed a multi-epitope-based vaccine against E. mundtii using in silico approaches. After an in-depth analysis of the core genome, three probable antigenic proteins (lytic polysaccharide monooxygenase, siderophore ABC transporter substrate-binding protein, and lytic polysaccharide monooxygenase) were shortlisted for epitope prediction. Among predicted epitopes, ten epitopes-GPADGRIAS, TTINHGGAQA, SERTALSVTT, GDGGNGGGEV, GIKEPDLEK, KQADDRIEA, QAIGGDTSN, EPLDEQTASR, AQWEPQSIEA, QPLKFSDFEL-were selected for multi-epitope vaccine construct designing. The screened B- and T-cell epitopes were joined with each other via specific linkers and linked to the cholera toxin B subunit as an adjuvant to enhance vaccine immune protection efficacy. The designed vaccine construct induced cellular and humoral immune responses. Blind docking with immune cell receptors, followed by molecular dynamic simulation results confirms the good binding potency and stability of the vaccine in providing protection against the pathogen.
Insights
A novel in silico vaccine was designed against Enterococcus mundtii, a key cause of hospital infections. This multi-epitope vaccine shows promise for inducing immune responses and protecting against this emerging pathogen.
Area of Science:
- Bacterial pathogenesis
- Vaccine development
- Computational biology
Background:
- Enterococcus species are significant causes of hospital-associated infections, with Enterococcus mundtii being a prominent pathogen.
- Multi-drug resistant strains and the lack of a licensed vaccine highlight the need for new intervention strategies.
- In silico vaccine design offers a promising alternative to experimental vaccinology for developing effective vaccines against challenging pathogens.
Purpose of the Study:
- To design a multi-epitope-based vaccine against Enterococcus mundtii using computational approaches.
- To identify and select potent antigenic proteins and epitopes for vaccine construct development.
- To evaluate the potential immunogenicity and stability of the designed vaccine candidate.
Main Methods:
- Core genome analysis to identify antigenic proteins.
- In silico epitope prediction (B-cell and T-cell epitopes).
- Multi-epitope vaccine construct design, including linking epitopes and incorporating cholera toxin B subunit as an adjuvant.
- In silico validation through blind docking and molecular dynamic simulations.
Main Results:
- Three antigenic proteins were identified, and ten epitopes were selected for vaccine design.
- The designed vaccine construct, linked with cholera toxin B subunit, showed potential for inducing both cellular and humoral immune responses.
- Molecular simulations confirmed the vaccine's good binding potency and stability against pathogen targets.
Conclusions:
- The in silico designed multi-epitope vaccine holds promise for effective protection against Enterococcus mundtii infections.
- Computational approaches can accelerate the development of vaccines against emerging and drug-resistant bacterial pathogens.
- Further experimental validation is warranted to confirm the efficacy of this novel vaccine candidate.
